远大医学营养科学（武汉）

Grand Medical Nutrition Science (Wuhan) Co., Ltd. (formerly Wuhan Daan Pharmacy and later Grand Life Science (Wuhan)) is a high-tech pharmaceutical company based in Wuhan, China, and a subsidiary of China Grand Enterprises. The company integrates R&D, manufacturing, and commercialization, focusing on medical nutrition, perioperative drugs, and nano-targeted drug delivery systems such as liposomes, emulsions, and microspheres. Its flagship commercial product, Flurbiprofen Axetil Injection (Anfu), is a widely used nano-targeted analgesic for postoperative pain management. Additionally, the company's pipeline includes DA002, an oral solution in Phase 3 clinical trials for urea cycle disorders, and DA001, an eye drop formulation in Phase 2 clinical trials for delaying myopia progression in children.